ArticleParkinson's disease2016
Rotigotine Objectively Improves Sleep in Parkinson's Disease: An Open-Label Pilot Study with Actigraphic Recording.
Article in Parkinson's disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 44 citations in OpenAlex.
- Efficacy and safety of rotigotine in elderly patients with Parkinson's disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials.Journal of neurology · 2018Trial
- Late-stage interventional trials reporting sleep-related outcomes in older adults with Parkinson's disease: a ClinicalTrials.gov registry review.BMC geriatrics · 2026Review
- Effects of rotigotine on sleep in Parkinson's disease patients: a Parkinson's KinetiGraph study.Frontiers in neurology · 2025Article
- Sleep Disturbance, Sleep Disorders and Co-Morbidities in the Care of the Older Person.Medical sciences (Basel, Switzerland) · 2021Review
- Rotigotine Transdermal Patch for Motor and Non-motor Parkinson's Disease: A Review of 12 Years' Clinical Experience.CNS drugs · 2021Review
- The Treatment of Sleep Dysfunction in Neurodegenerative Disorders.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Review
- Sleep Issues in Parkinson's Disease and Their Management.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
- Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson's disease.Journal of neurology · 2019Article
- Management Recommendations on Sleep Disturbance of Patients with Parkinson's Disease.Chinese medical journal · 2018Article
- A Pilot Study to Determine the Consistency of Simultaneous Sleep Actigraphy Measurements Comparing All Four Limbs of Patients with Parkinson Disease.Geriatrics (Basel, Switzerland) · 2017Article
- The Treatment of Sleep Disorders in Parkinson's Disease: From Research to Clinical Practice.Frontiers in neurology · 2017Review
- Rotigotine transdermal patch and sleep in Parkinson's disease: where are we now?NPJ Parkinson's disease · 2017Review
- New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson's Disease.Current pharmacology reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sleep disturbances represent important predictors of poor quality of life (QoL) in Parkinson's disease (PD). This open-label pilot study aimed to objectively assess, by means of actigraphic recording, effect of rotigotine on sleep in PD patients with self-reported sleep complaints. 15 PD patients underwent one-week actigraphic recording before (T0) and during (T1) rotigotine treatment, which was titrated to the dose subjectively improving motor symptoms (4-8 mg/24 h). Sleep disturbances, daytime sleepiness, cognitive performance, QoL, and depression were also evaluated with questionnaires. Actigraphic recordings showed a significant reduction in nocturnal motor activity and mean duration of wake episodes after sleep onset during rotigotine treatment compared to baseline. In 10 patients presenting objective evidence of poor sleep quality at T0 (sleep efficiency ≤ 85%), rotigotine also significantly improved other sleep parameters and further reduced nocturnal motor activity and mean duration of wake episodes. A significant decrease in number and duration of daytime sleep episodes was also observed at T1. Finally we confirmed that rotigotine significantly improves perceived sleep quality and QoL. Our study showed for the first time that rotigotine is associated with an objective improvement of nocturnal and diurnal sleep disturbances in PD patients with self-reported sleep complaints. This study is registered with AIFA-observational study registry number 12021.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.